Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
| Indexado |
|
||||
| DOI | 10.1016/S0140-6736(22)00152-0 | ||||
| Año | 2022 | ||||
| Tipo | revisión |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Abstract
Interpretation COVID-19 vaccine efficacy or effectiveness against severe disease remained high, although it did decrease somewhat by 6 months after full vaccination. By contrast, vaccine efficacy or effectiveness against infection and symptomatic disease decreased approximately 20-30 percentage points by 6 months. The decrease in vaccine efficacy or effectiveness is likely caused by, at least in part, waning immunity, although an effect of bias cannot be ruled out. Evaluating vaccine efficacy or effectiveness beyond 6 months will be crucial for updating COVID-19 vaccine policy. Copyright (C) 2022 The Author(s). Published by Elsevier Ltd.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Feikin, Daniel R. | Hombre |
WHO - Suiza
Organisation Mondiale de la Santé - Suiza |
| 2 | Higdon, Melissa M. | Mujer |
Johns Hopkins Bloomberg Sch Publ Hlth - Estados Unidos
Johns Hopkins Bloomberg School of Public Health - Estados Unidos |
| 3 | Abu-Raddad, Laith J. | Hombre |
Weill Cornell Med Qatar - Catar
Weill Cornell Medicine-Qatar - Catar |
| 4 | Andrews, Nick | Hombre |
Hlth Secur Agcy - Reino Unido
UK Health Security Agency - Reino Unido |
| 5 | ARAOS-BRALIC, RAFAEL IGNACIO | Hombre |
Universidad del Desarrollo - Chile
Advanced Center for Chronic Diseases - Chile |
| 6 | Goldberg, Yair | Hombre |
Technion Israel Inst Technol - Israel
Technion - Israel Institute of Technology - Israel |
| 7 | Groome, Michelle J. | Mujer |
Natl Inst Communicable Dis - República de Sudáfrica
Univ Witwatersrand - República de Sudáfrica National Institute for Communicable Diseases - República de Sudáfrica School of Pathology - República de Sudáfrica |
| 8 | Huppert, Amit | Hombre |
Tel Aviv Univ - Israel
Tel Aviv University - Israel |
| 9 | O'Brien, Katherine L. | Mujer |
WHO - Suiza
Organisation Mondiale de la Santé - Suiza |
| 10 | Zambon, Maria | Mujer |
London Sch Hyg & Trop Med - Reino Unido
Medical Research Council - Reino Unido |
| 11 | Wilder-Smith, Annelies | Mujer |
WHO - Suiza
Organisation Mondiale de la Santé - Suiza |
| 12 | Zeger, Scott | Hombre |
Johns Hopkins Bloomberg Sch Publ Hlth - Estados Unidos
Johns Hopkins Bloomberg School of Public Health - Estados Unidos |
| 13 | Knoll, Maria Deloria | Mujer |
Johns Hopkins Bloomberg Sch Publ Hlth - Estados Unidos
|
| 13 | Deloria-Knoll, Maria | Mujer |
Johns Hopkins Bloomberg School of Public Health - Estados Unidos
|
| 14 | Patel, Minal K. | Mujer |
WHO - Suiza
Organisation Mondiale de la Santé - Suiza |
| Fuente |
|---|
| South African Medical Research Council |
| World Health Organization |
| Israel Science Foundation |
| United States-Israel Binational Science Foundation |
| Bill and Melinda Gates Foundation |
| Merck |
| Centers for Disease Control and Prevention |
| University of North Carolina Wilmington |
| Mayo Clinic |
| Asian Development Bank |
| Coalition for Epidemic Preparedness Innovations |
| Chile Ministry of Science |
| Agradecimiento |
|---|
| Coalition for Epidemic Preparedness Innovations. |
| We want to acknowledge the important contribution of the following individuals in being able to undertake this analysis: Anurima Baidya, Karoline Walter, Siqi Li, Hanane Issa, Parisa ShamaeiZadeh, and Marely Jurgensmeyer. We thank Dan-Yu Lin from the University of North Carolina, Chapel Hill, NC, USA for providing exact vaccine effectiveness estimates and CIs for his study. We also thank Alison L Hill and Yu Bin Na for their technical assistance in producing the figures. |
| We want to acknowledge the important contribution of the following individuals in being able to undertake this analysis: Anurima Baidya, Karoline Walter, Siqi Li, Hanane Issa, Parisa ShamaeiZadeh, and Marely Jurgensmeyer. We thank Dan-Yu Lin from the University of North Carolina, Chapel Hill, NC, USA for providing exact vaccine effectiveness estimates and CIs for his study. We also thank Alison L Hill and Yu Bin Na for their technical assistance in producing the figures. |
